Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study-Reference-Cited by-同舟云学术

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

Published:2022-04 Issue:4 Volume:9 Page:e289-e300
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Casulo Carla,Larson Melissa C,Lunde Julianne J,Habermann Thomas M,Lossos Izidore S,Wang Yucai,Nastoupil Loretta J,Strouse Christopher,Chihara Dai,Martin Peter,Cohen Jonathon B,Kahl Brad S,Burack W Richard,Koff Jean L,Mun Yong,Masaquel Anthony,Wu Mei,Wei Michael C,Shewade Ashwini,Li Jia,Cerhan James,Flowers Christopher R,Link Brian K,Maurer Matthew J

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5);Mounier;Lancet Haematol,2015

3. Rituximab plus lenalidomide in advanced untreated follicular lymphoma;Morschhauser;N Engl J Med,2018

4. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study;Flinn;Blood,2014

5. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016;Press;J Clin Oncol,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-02

2. An assessment model for efficacy of patients with relapsed or refractory diffuse large B-cell lymphoma following autologous CD19 chimeric antigen receptor T-cell therapy.;2023-12-14

3. Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia;Hematology/Oncology Clinics of North America;2023-12

4. Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China;Frontiers in Oncology;2023-10-24

5. Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma;Oncology and Therapy;2023-10-18